BridgeBio Pharma reported that its ATTR‑CM drug Attruby generated $146.0 million in unaudited Q4 2025 net product revenue, up 35% from the $108.1 million recorded in Q3 2025. Full‑year 2025 revenue reached $362.4 million, reflecting a rapid uptake of the drug in the United States after its November 2024 FDA approval. The company’s commercial team noted that 6,629 unique patients were treated and 1,632 prescribers issued prescriptions by December 31, 2025, a 20% increase in prescriber participation that underscores growing physician confidence and patient access.
BridgeBio also highlighted several late‑stage pipeline programs. A new TTR amyloid depleter antibody is slated to enter clinical trials between 2027 and 2028. Phase 3 readouts for BBP‑418 (LGMD2I) and encaleret (ADH1) were announced, with FDA‑recommended NDA submissions planned for the first half of 2026. A Phase 3 trial of encaleret in chronic hypoparathyroidism is scheduled for summer 2026, and the company achieved a Level‑of‑Proof‑V for PROPEL 3, the Phase 3 study of infigratinib in children with achondroplasia, with topline results expected by the end of Q1 2026.
BridgeBio’s cash, cash equivalents, and marketable securities totaled $587.5 million as of December 31, 2025. The liquidity position provides a solid foundation to sustain Attruby’s commercial acceleration and to support the potential launch of three additional medicines worldwide in 2026, as the company indicated it is preparing for a broader product portfolio expansion.
The commercial performance of Attruby demonstrates BridgeBio’s ability to translate clinical differentiation into market adoption. The 35% quarterly revenue growth and expanding prescriber base suggest that the drug is gaining traction as a first‑choice therapy for newly diagnosed ATTR‑CM patients. Simultaneously, the pipeline milestones signal a robust development pipeline that could deliver additional revenue streams in the near term, reinforcing the company’s growth trajectory and supporting its strategic focus on rapid, patient‑centric delivery of therapies.
BridgeBio’s disclosures illustrate a company that is successfully monetizing its flagship product while advancing a diversified pipeline. The combination of strong Attruby sales, significant cash reserves, and multiple late‑stage programs positions BridgeBio to capitalize on market opportunities and to maintain momentum in the coming years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.